Pharmacists in Garberville, CA Accepting Medicare

3 Pharmacists found. Showing 1 - 3

Jane Douglas Hollis, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 875 Redwood Dr, Garberville, CA 95542 Phone: 707-923-2461

Mr. Brian Dale Winterberg, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 875 Redwood Dr, Garberville, CA 95542 Phone: 707-923-2461    Fax: 707-923-4038

Dr. Bryan R Coleman, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 286 Sprowel Creek Rd, Garberville, CA 95542 Phone: 707-921-7078    Fax: 707-921-7069

News Archive

AngioScore launches AngioSculpt PTA Scoring Balloon Catheters for treatment of PAD

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of new, longer AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease.

First clinical trial to test use of retinal progenitor cells for treating retinitis pigmentosa begins

Participants are being enrolled in the first clinical trial that tests the use of retinal progenitor cells to treat retinitis pigmentosa, reported project director Dr. Henry Klassen of UCI's Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center. The product of stem cell research at UCI, these retinal progenitors are similar to stem cells in terms of potential regenerative properties, but they're specific to the retina.

SARS-CoV-2 saliva testing that omits the RNA extraction step

Even as the COVID-19 pandemic progresses throughout the world, the lack of consistent diagnostic testing has been a bugbear, preventing public health control of the spread of infection. A new study by researchers at the University of Illinois Urbana-Champaign and published on the preprint server bioRxiv in June 2020 reports a new testing method that uses saliva, does not require RNA extraction, and can be scaled up quickly and inexpensively.

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

WHO provides medicines, related health supplies to flood-affected areas in Pakistan

The worst floods on record in Pakistan are placing the health of hundreds of thousands of people at risk, with a high threat of waterborne disease outbreaks and immense damage to health facilities. WHO is coordinating the response of health partners and supporting Pakistani authorities by sending medicines and related health supplies capable of treating more than 200 000 people to the affected areas in the northwestern region of the country.

Read more Medical News

› Verified 7 days ago